Hypertensive disorders of pregnancy and risk of cardiovascular disease: A Mendelian Randomisation study in the UK Biobank

Lena Tschiderer, PhD,^{1,2} Yvonne T van der Schouw, PhD,² Stephen Burgess, PhD,^{3,4,5} Kitty WM Bloemenkamp, PhD,⁶ Lisa Seekircher, PhD,¹ Peter Willeit, PhD,^{1,3} N Charlotte Onland-Moret, PhD,² Sanne AE Peters, PhD^{2,7,8}

¹Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria; ²Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands; ³Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ⁴Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom; ⁵MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ⁶Department of Obstetrics, Division Women and Baby, Birth Centre Wilhelmina Children Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands; ⁷The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom; ⁸The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.

Short title: Hypertensive disorders of pregnancy & CVD risk

Correspondence to:

Sanne AE Peters Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands Phone: +31887568181 E-mail: S.A.E.Peters@umcutrecht.nl

Word count: 5,992; 1 Table; 4 Figures

1 Abstract

Background: Observational studies show that hypertensive disorders of pregnancy
(HDPs) are related to unfavourable maternal cardiovascular disease (CVD) risk
profiles later in life. We investigated whether genetic liability to preeclampsia/eclampsia and gestational hypertension is associated with CVD risk
factors and occurrence of CVD events.

7 **Methods:** We obtained genetic associations with HDPs from a genome-wide 8 association study and used individual-participant-data of women and men from the 9 UK Biobank to obtain genetic associations with CVD risk factors and CVD events 10 (defined as myocardial infarction or stroke). The rationale for including men and 11 nulligravidae was to study genetic liability to HDPs and CVD risk without 12 experiencing the underlying phenotype. We applied Mendelian Randomisation 13 analysis using inverse variance weighted regression in our primary analysis.

14 **Results:** We included 264,160 women (mean age 56.4 [SD 8.0]) and 223,043 men 15 (mean age 56.7 [8.2]) with available genetic data. Genetically proxied pre-16 eclampsia/eclampsia was related to higher risk of CVD with odds ratios of 1.20 (1.01, 17 1.43) and 1.29 (1.08, 1.53) in women and men, respectively. For genetically proxied 18 gestational hypertension, odds ratios for CVD were 1.22 (1.10, 1.36) and 1.28 (1.16, 19 1.42) in women and men, respectively. Furthermore, genetically proxied HDPs were 20 associated with higher levels of systolic and diastolic blood pressure and younger 21 age at hypertension diagnosis in both women and men.

22 Conclusions: Genetic liability to HDPs including pre-eclampsia/eclampsia and 23 gestational hypertension is associated with higher CVD risk, implying biological 24 mechanisms relating to these disorders are causally related to CVD risk in both 25 women and men.

26 Introduction

27 Hypertensive disorders of pregnancy (HDPs) affected one in eight hospital deliveries 28 in 2019 and came along with one in four maternal deaths between 2017 and 2019 in 29 the US.¹ Globally, there were 18.1 million incident cases of hypertensive pregnancy disorders in 2019.² They can express as different phenotypes including gestational 30 31 hypertension, pre-eclampsia/eclampsia, and HELLP syndrome. Pre-eclampsia is a 32 multi-organ disease originating from a dysfunction of the placenta and affects approximately one in twenty deliveries.^{3,4} The International Society for the Study of 33 34 Hypertension in Pregnancy defines pre-eclampsia as gestational hypertension with 35 one or more of the following concomitants: (1) proteinuria, (2) other maternal organ 36 dysfunction (acute kidney injury, liver involvement, neurological or haematological complications), or (3) uteroplacental dysfunction.⁵ Eclampsia is a progression of pre-37 eclampsia, in which women additionally experience seizures.⁶ Gestational 38 39 hypertension is defined as *de novo* hypertension at ≥20 weeks of gestation without 40 the additional signs of pre-eclampsia.⁵

A range of risk factors for HDPs have been proposed including higher pre-pregnancy 41 42 body mass index (BMI), pre-pregnancy diabetes mellitus, chronic hypertension, chronic autoimmune disease, and maternal age.^{7,8} Furthermore, HDPs are related to 43 44 multiple immediate, short-term, and long-term health concerns, which can affect the 45 mother and the foetus and neonate.⁹ Short-term outcomes are, for instance, stillbirth and preterm delivery,⁹ whereas on the long term HDPs are associated with maternal 46 47 risk factors cardiovascular after pregnancy including diabetes mellitus, hyperlipidaemia, and hypertension.⁹ Observational studies have also reported a 48 relation between HDPs and higher risk of maternal cardiovascular disease (CVD) 49 events later in life,⁹ which has been confirmed in co-sibling analyses¹⁰ and by a 50 51 previous Mendelian Randomisation (MR) study that was restricted to sex-combined 52 genetic associations with CVD events.¹¹

However, the specific biological mechanisms behind HDPs and CVD risk are not entirely clear. As HDPs and CVD share a considerable amount of risk factors, the theory emerged that both phenotypes are expressions of the same disease pathway at different stages in life,¹² and that pregnancy enables earlier identification of

57 women at higher CVD risk.¹³ Apart from that, HDPs could also cause long-term 58 vascular damage leading to a higher CVD risk later in life.¹³

59 To better understand the role of HDPs in the development of CVD, we conducted a 60 MR analysis of 487,203 women and men from the UK Biobank with the aim to 61 estimate the sex-specific relation of genetic liability to pre-eclampsia/eclampsia and 62 gestational hypertension with CVD events, blood pressure-traits, and lipid-, liver-, 63 and kidney-related cardiovascular risk factors. The rationale for also analysing men 64 and nulligravidae was to study the role of genetic liability to HDPs in cardiovascular 65 risk without experiencing the underlying phenotype, which could help understand 66 whether biological mechanisms related to HDPs or the diseases themselves are 67 responsible for higher CVD risk.

68 Methods

This analysis adheres to the STROBE-MR statement (**Table S1**).¹⁴ Please see the
Major Resources Table in the Supplemental Materials.

71 Study design and data sources

The present study included data from the UK Biobank, of which details have been described previously.¹⁵ Briefly, the UK Biobank is a large-scale prospective study in the general population of the UK, in which over 500,000 individuals aged 40 to 69 years were recruited between 2006 and 2010.¹⁵ The UK Biobank was approved by the North-West Multi-Centre Research Ethics Committee and all participants provided written informed consent.

For the MR analysis, we used individual-level imputed data on genetic variants. Genotyping was performed using the Affymetrix UK BiLEVE Axiom array and the Affymetrix UK Biobank Axiom Array.^{16,17} Genotype imputation was based on the Haplotype Reference Consortium and the UK10K haplotype reference panel.¹⁸

Of the 502,412 UK Biobank participants, we excluded 15,209 individuals because
they had missing values on the genetic variants included in our analysis. The
remaining 487,203 individuals contributed to the present analysis.

85 Specific definitions of pre-eclampsia/eclampsia, gestational hypertension, CVD
86 events, and additional variables are outlined in Supplementary Methods.

87 Statistical analysis

We summarised continuous variables with mean and standard deviation (SD), if normally distributed, and with median and interquartile range, otherwise. Categorical variables were summarised with number and percentage. For all analyses, we used two-sided statistical tests and deemed P-values≤0.05 as statistically significant. Analyses were carried out using R 4.0.5 (The R Foundation, Vienna, Austria).

93 Instrumental variable

For our instrumental variables, we used SNPs for pre-eclampsia/eclampsia and gestational hypertension identified by a recent genome-wide association study (GWAS) by Honigberg et al.¹⁹ We used effect sizes and standard errors from the discovery analysis, which excluded data from the UK Biobank, allowing two-sample MR.¹⁹

99 As illustrated in Figure S1, twelve SNPs for pre-eclampsia/eclampsia and seven SNPs for gestational hypertension were identified by the GWAS.¹⁹ We harmonised 100 the summary-level data to be represented on the same strand. Furthermore, we 101 102 excluded palindromic SNPs with allele frequencies between 0.45 and 0.55. For both 103 exposures, we excluded one palindromic SNP (rs9855086). To identify related traits, we scanned Phenoscanner²⁰ (on February 14th 2023) and extracted all traits 104 associated with the SNPs or any proxies in high linkage disequilibrium ($R^2 \ge 0.8$) with 105 106 P-values≤5×10⁻⁸ omitting traits identified from the UK Biobank by Neale et al. 107 (http://www.nealelab.is/uk-biobank/). Details on the SNPs included in the present 108 analysis and related traits are provided in Table S2.

We measured the strength of our instrumental variable based on the F-statistics ofeach SNP individually, which ranged from 30 to 58.

111 Primary analysis

We conducted all analyses sex-specific and for women and men combined. For the association between the genetic variants and CVD events, we implemented logistic regression adjusting for age at baseline, sex, if appropriate, and the first 16 genetic principal components, as suggested previously.²¹ We conducted the MR analysis

using the R-package *MendelianRandomization*.²² In the primary analysis, we applied inverse variance weighted (IVW) regression. We obtained women-to-men ratios of odds ratios (ORs) and 95% confidence intervals (CIs) by subtracting logORs for men from logORs for women and adding sex-specific variances. All ORs in MR analyses are reported per unit increase in the log odds of genetically proxied preeclampsia/eclampsia and gestational hypertension.

122 Sensitivity analyses

Sensitivity analyses were conducted similarly to the primary analysis but by applying
 simple and weighted median regression, MR-Egger, and MR-PRESSO.²³

Furthermore, we studied associations between genetic variants and CVD events using a Cox proportional hazards model. We used age as underlying timescale and adjusted for sex, if appropriate, and the first 16 genetic principal components. For this sensitivity analysis we excluded all individuals with history of CVD (defined as myocardial infarction or stroke) at baseline. Time-to-event was defined as time to the first CVD event, death, or end of follow-up, whichever occurred first.

131 Moreover, we conducted a sensitivity analysis, classifying women into ever and 132 never pregnant. We obtained ever-to-never-pregnant ratios of ORs and 95% Cls by 133 subtracting logORs for never pregnant from logORs for ever pregnant women and 134 adding corresponding variances.

135 Secondary analyses

136 In addition, we conducted a MR analysis using a set of cardiovascular risk factors as 137 outcome variables. We analysed blood pressure-related traits including systolic 138 blood pressure (SBP), diastolic blood pressure (DBP), and age at hypertension 139 diagnosis. Furthermore, we analysed additional CVD risk factors including BMI, total 140 cholesterol, high-density lipoprotein cholesterol, triglycerides, low-density lipoprotein 141 cholesterol, lipoprotein(a), apolipoprotein A1, apolipoprotein B, HbA1c, creatinine, 142 albumin, ALAT, ASAT, GGT, and C-reactive protein. For obtaining genetic 143 associations with risk factors, we used linear regression analysis adjusting for age, 144 sex, if appropriate, and the first 16 genetic principal components,²¹ and divided all 145 cardiovascular risk factors by their SD to enhance the comparison between the 146 individual risk factors. The MR analysis was based on IVW regression.

147 **Results**

148 Characteristics of the study population

Baseline characteristics of the included participants are outlined in **Table 1**. The present analysis included 264,160 (54%) women and 223,043 (46%) men. Mean age at baseline was 56.5 (SD 8.1) years. CVD was reported in 13,861 women (7,232 myocardial infarctions; 7,436 strokes) and 27,682 men (19,746 myocardial infarctions; 10,104 strokes).

154 MR analysis of genetically proxied HDPs and risk of CVD

155 **Primary analysis**

As depicted in **Figure 1**, in women and men, respectively, genetically proxied preeclampsia/eclampsia was related to a higher risk of CVD with ORs of 1.20 (95% CI 1.01, 1.43) and 1.29 (1.08, 1.53) and to a higher risk of ischaemic CVD with ORs of 1.24 (1.02, 1.52) and 1.32 (1.10, 1.59). We found no significant association with risk of haemorrhagic stroke. Women-to-men ratios of ORs revealed no differences between sexes.

Figure 2 shows the MR analyses for gestational hypertension and CVD events. In women and men, respectively, ORs were 1.22 (1.10, 1.36) and 1.28 (1.16, 1.42) for CVD and 1.22 (1.10, 1.37) and 1.32 (1.19, 1.47) for ischaemic CVD. ORs for haemorrhagic stroke were 1.37 (1.07, 1.77) and 1.12 (0.72, 1.75) in women and men, respectively. Again, women-to-men ratios of ORs were not statistically significantly different from one.

In sex-combined analyses both genetically proxied HDPs were related to a higher
risk of CVD, ischaemic CVD, myocardial infarction, stroke, and ischaemic stroke, but
not with haemorrhagic stroke and intracerebral haemorrhage (Figure S2 and Figure
S3). Genetically proxied gestational hypertension but not pre-eclampsia/eclampsia
was associated with higher risk of subarachnoid haemorrhage.

173 Sensitivity analyses

In sensitivity analyses, applying simple and weighted median regression, results
were broadly similar when investigating genetically proxied pre-eclampsia/eclampsia
in women (Figure S4), men (Figure S5), and women and men combined (Figure

177 S6). When applying MR-Egger, the OR for intracerebral haemorrhage was 6.21 178 (1.16, 33.31) in the sex-combined analysis with indication of directional pleiotropy (P-179 value intercept=0.027). ORs from MR-Egger regression for all other cardiovascular 180 events were not statistically significant. **Table S3** shows the results of MR-PRESSO, 181 which detected outlying variants in the analysis of women, men, and in the sex-182 combined analysis. The effect sizes remained similar but the association between 183 genetically proxied pre-eclampsia/eclampsia and higher risk of myocardial infarction 184 in women became statistically significant.

185 When analysing genetically proxied gestational hypertension, results remained 186 robust when implementing simple or median weighted regression for the analysis in 187 women (Figure S7), in men (Figure S8), and in sex-combined analyses (Figure S9). 188 In women, MR-Egger regression yielded a statistically significant intercept (P-189 value=0.002) when analysing the combined stroke endpoint (Figure S7). Table S3 shows the results of MR-PRESSO, in which genetically proxied gestational 190 191 hypertension was statistically significantly related to a higher risk of haemorrhagic 192 stroke in the sex-combined analysis (OR 1.32 [1.22, 1.44]).

193 The Cox regression analysis included 258,416 women and 209,387 men without a 194 history of CVD at baseline. As depicted in **Figure S10**, results remained broadly 195 similar compared the primary analysis. Genetically proxied to pre-196 eclampsia/eclampsia was related to hazard ratios of 1.13 (0.95, 1.34) and 1.20 (1.01, 197 1.44) for CVD in women and men, respectively, with no significant differences 198 between the sexes. Hazard ratios for CVD were 1.17 (1.03, 1.32) in women and 1.25 199 (1.13, 1.38) in men, when analysing genetically proxied gestational hypertension 200 (Figure S11). Results of the sex-combined analysis are provided in Figure S12 and 201 **Figure S13** and were also comparable to the findings of the primary analysis.

Figure S14 and Figure S15 show the MR analyses by history of pregnancy. The excess risk for ischaemic stroke for genetic liability to gestational hypertension was higher in ever compared to never pregnant women with a ratio of ORs of 1.84 (1.04, 3.24). We found no significant differences when analysing pre-eclampsia/eclampsia and gestational hypertension and other CVD events.

207 MR analysis of genetically proxied HDPs with blood pressure-traits

208 and cardiovascular risk factors

209 Figure 3 shows the associations genetically between proxied pre-210 eclampsia/eclampsia and a range of cardiovascular risk factors. Genetically proxied 211 pre-eclampsia/eclampsia was related to higher levels of SBP and DBP and younger 212 age at hypertension diagnosis. Furthermore, we found a significant association with 213 lower levels of total cholesterol in both women and men. There were no sex-214 differences in any of the associations.

Relations between genetically proxied gestational hypertension and cardiovascular risk factors are depicted in **Figure 4**. Genetically proxied gestational hypertension was associated with higher levels of SBP and DBP and younger age at hypertension diagnosis in women and men with no statistically significant differences between women and men.

220 Sex-combined analyses for genetically proxied pre-eclampsia/eclampsia and 221 gestational hypertension are shown in Figure S16 and Figure S17, respectively. 222 Again. genetically proxied pre-eclampsia/eclampsia and both destational 223 hypertension were related to higher levels of SBP and DBP and younger age at 224 hypertension diagnosis. Additionally, genetically proxied pre-eclampsia/eclampsia 225 was associated with lower levels of several lipid parameters.

226 **Discussion**

In this analysis, we found associations between genetic liability to preeclampsia/eclampsia and gestational hypertension and higher risk of CVD in both
women and men. Furthermore, both HDPs were related to higher levels of SBP and
DBP and younger age at hypertension diagnosis.

231 Findings from previous studies

A positive association between HDPs and risk of CVD has previously been reported by observational studies. A large-scale meta-analysis showed that moderate and severe pre-eclampsia are associated with a higher risk of maternal CVD, with ORs of 2.24 (1.72, 2.93) and 2.74 (2.48, 3.04), respectively.²⁴ The same is the case for

236 gestational hypertension, for which an OR for maternal CVD of 1.67 (1.28, 2.19) has been reported.²⁴ Moreover, a phenome-wide association analysis showed strong 237 238 associations between polygenic risk scores of HDPs with CVD risk factors (such as 239 hypertension, diabetes mellitus, hyperlipidaemia, and obesity) and CVD events 240 (including ischaemic heart disease and coronary atherosclerosis) in women and 241 men.¹⁹ In addition, a recent MR analysis, which only included women for genetic associations with HDPs, showed genetically proxied HDPs to be related to a higher 242 risk of coronary artery disease or ischaemic stroke.¹¹ Furthermore, genetically 243 244 proxied pre-eclampsia and gestational hypertension were associated with a higher 245 risk of coronary artery disease but not with risk of ischaemic stroke.¹¹ This is not in 246 line with the results of the present study, in which we did find a significantly higher 247 risk for ischaemic stroke for genetically proxied pre-eclampsia/eclampsia in women. 248 However, it has to be noted that the previous MR study only included data from one 249 database for obtaining genetic associations with genetically proxied HDPs and used 250 sex-combined effect sizes for the genetic associations with CVD events, which could potentially explain these differences.¹¹ In the present MR study, we (1) used effect 251 252 sizes for the genetic association with the exposure from a large-scale GWAS that 253 meta-analysed results of multiple studies, (2) analysed sex-specific effect sizes for 254 the genetic association with the outcome, (3) included analyses restricted to men, 255 and (4) studied associations with blood pressure-, lipid-, liver-, and kidney-related 256 traits.

257 HDPs and blood pressure

258 Per definition, hypertension is the major component of HDPs. In the present 259 analysis, we showed that genetically proxied pre-eclampsia/eclampsia and 260 gestational hypertension are significantly associated with both higher SBP and DBP 261 later in life. Genetic correlation between HDPs and blood pressure has previously been demonstrated.¹⁹ Notably, the genetic correlation between gestational 262 hypertension and SBP was even higher than between SBP and DBP.¹⁹ A previous 263 264 MR analysis showed that higher genetically predicted SBP was also related to an elevated risk for pre-eclampsia/eclampsia.²⁵ Moreover, higher levels of genetically 265 266 proxied blood pressure have been related to an increased risk of CVD in both 267 women and men.²⁶ In case blood pressure lies on the causal pathway between pre-268 eclampsia/eclampsia and gestational hypertension and CVD, we speak of vertical

269 pleiotropy, which does not bias the findings of our MR analysis. However, we cannot 270 fully exclude horizontal pleiotropy, which would violate the assumptions of MR. When 271 applying MR-Egger, we found no significant intercepts in the relation of pre-272 eclampsia/eclampsia and CVD, which indicates absence of directional pleiotropy. 273 We did find a significant MR-Egger intercept in the association between genetically 274 proxied gestational hypertension and risk of stroke and ischaemic stroke in women. 275 However, it has previously been discussed that MR-Egger results can be influenced 276 by outlying variants.²⁷ When we further studied the relation between genetically 277 proxied gestational hypertension and risk of stroke and ischaemic stroke applying 278 MR-PRESSO, the findings of our primary analysis remained robust.

279 Differences between ischaemic and haemorrhagic events

280 MR analysis revealed both pre-eclampsia/eclampsia and gestational Our 281 hypertension to be related to ischaemic CVD. Contrarily, we found no statistically 282 significant association between pre-eclampsia/eclampsia and risk of haemorrhagic 283 stroke. These findings are not in line with results from previous observational 284 studies. In a US database it has been shown that pre-eclampsia/eclampsia was 285 associated with an OR for pregnancy-related intracerebral haemorrhage of 10.39 (8.32, 12.98).²⁸ Moreover, a study from Taiwan reported a hazard ratio for 286 haemorrhagic stroke of 3.50 (2.31, 5.29) related to pre-eclampsia.²⁹ Another analysis 287 288 in Canadian women found pre-eclampsia to be related to a higher risk of haemorrhagic stroke.³⁰ Therefore, our findings suggest that the results of 289 290 observational studies may be biased by potential confounding factors affecting the 291 relation between pre-eclampsia/eclampsia and risk of haemorrhagic stroke. 292 However, especially our sex-specific analysis may have limited statistical power to 293 analyse haemorrhagic stroke events, which could have prevented us from finding 294 statistically significant associations. Nevertheless, in sex-combined analyses, we 295 did also not find significant association of genetically proxied pre-296 eclampsia/eclampsia and occurrence of haemorrhagic stroke. In contrast, we did find 297 a statistically significant association between genetically proxied gestational 298 hypertension and the risk of subarachnoid haemorrhage in our sex-combined 299 analysis. This indicates potential differences between the roles of pre-300 eclampsia/eclampsia and gestational hypertension in the risk for haemorrhagic 301 stroke.

302 HDPs in men and nulligravidae

303 Our MR analysis also included men and nulligravidae, who can have the genetic 304 liability to HDPs although the underlying phenotype can never express. 305 Nevertheless, we found genetic liability to pre-eclampsia/eclampsia and gestational 306 hypertension to be related to a higher risk of CVD events in men. Robillard et al. 307 previously suggested the importance paternity in the development of pre-eclampsia 308 and reported a significantly higher risk for pre-eclampsia in new paternity multiparas compared to same paternity multiparas and primiparas.³¹ To further investigate how 309 310 the genetic liability to HDPs expresses in men, we studied their relationship with a 311 range of cardiovascular risk factors. Interestingly, genetically proxied HDPs were 312 also related to younger age at hypertension diagnosis in men. A recently conducted 313 phenome-wide association study investigated the relation between polygenic risk 314 scores for pre-eclampsia/eclampsia and gestational hypertension with >1,000 315 phenotypes in men and also reported hypertension to be one of the key associated characteristics.¹⁹ This is indicative that earlier hypertension is a main driver of the 316 317 underlying mechanisms leading to a higher CVD risk in males. We also analysed the 318 genetic liability to HDPs and CVD in nulligravidae. Relations were similar in never 319 and ever pregnant women for all CVD events, but ischaemic stroke, as we found a 320 statistically significantly higher excess risk for ischaemic stroke related to the genetic 321 liability to gestational hypertension for ever compared to never pregnant women. 322 However, it should be noted that statistical power for the analysis of nulligravid 323 women was limited. Consequently, the role of genetic liability to HDPs in CVD risk in 324 nulligravidae needs further investigation.

325 Strengths and limitations

326 Our study has several strengths. We used data from UK Biobank, which provided 327 adequate statistical power to conduct the MR analyses. Furthermore, we built our 328 genetic instruments on a comprehensive large-scale GWAS that meta-analysed data from multiple studies.¹⁹ Moreover, due to the use of individual-participant data from 329 330 the UK Biobank, we were able to study sex-specific associations of genetic variants 331 with CVD events. In addition, we conducted several sensitivity analyses including 332 different methods of MR and a Cox-regression analysis based on time-to-event data. 333 Our analysis also has limitations. First, the effect sizes for the genetic association

334 with the exposure variable were based on individuals of different ancestries, while 335 the UK Biobank majorly includes individuals of European ancestry. Furthermore, we 336 did not have adequate statistical power for analysing nulligravid women, limiting the 337 interpretation of our findings. Moreover, MR analysis relies on three assumptions. 338 The first assumption is that the instrumental variable is associated with the exposure. 339 Phenotypic data on pre-eclampsia/eclampsia and gestational hypertension were not 340 available in our dataset. Consequently, we were not able to investigate whether the 341 genetic instruments correlated with the phenotype in our study. However, we 342 calculated F-statistics for each SNP individually and all of them were ≥30 indicating 343 that we have sufficiently strong instruments. In addition, these SNPs were obtained from an independent GWAS, which replicated the majority of associations in 344 345 additional cohorts, supporting our assumption of having robust associations with the 346 exposures. The second assumption is that the genetic instrument is not associated 347 to any confounding factor. We studied the association of genetically proxied pre-348 eclampsia/eclampsia and gestational hypertension with several cardiovascular risk 349 factors. We found significant associations between genetically predicted HDPs and 350 lower levels of lipid parameters. As lower levels of some lipid parameters (e.g., total 351 cholesterol) are known to be related to a lower cardiovascular risk,³² while others 352 have been related to a higher cardiovascular risk (e.g., high-density lipoprotein cholesterol),³³ the specific role of lipid levels on the pathway between HDPs and risk 353 354 of cardiovascular events needs to be further investigated. The third assumption is 355 that the genetic instrument can influence the outcome only via the exposure. To 356 study this assumption, we conducted MR-Egger regression and MR-PRESSO, which 357 indicated potential directional pleiotropy for single CVD events as discussed in detail 358 above.

359 **Conclusion**

360 Genetic liability to HDPs including pre-eclampsia/eclampsia and gestational 361 hypertension is associated with higher CVD risk, implying biological mechanisms 362 relating to these disorders are causally related to CVD risk in both women and men.

363 **Perspectives**

364 This MR study demonstrated that genetic liability to pre-eclampsia/eclampsia and 365 gestational hypertension is related to a higher risk for CVD. Additionally, genetic 366 liability to HDPs was related to higher blood pressure levels and younger age at 367 hypertension diagnosis. The findings were similar in women and men. This implies 368 that biological mechanisms related to HDPs are causally related to CVD risk. 369 Furthermore, it suggests that both HDPs and CVD events may be expressions of the 370 same disease pathway at different stages in life and that HDPs may be an indicator 371 for individuals at higher CVD risk later in life. While pregnancy allows identification of 372 women at increased risk for future CVD, men and nulligravidae with the same 373 genetic liability to HDPs may not have the opportunity to present at an earlier stage 374 in life.

375 Acknowledgements

This research has been conducted using the UK Biobank Resource (Application Number 29916). We are extremely grateful to all participants in the UK Biobank.

378 Sources of Funding

This work was funded by the Austrian Science Fund (T 1253). SAEP is supported by a VIDI Fellowship from the Dutch Organisation for Health Research and Development (ZonMw) (09150172010050).

382 Disclosures

383 None.

384 Data availability

| 385 | Summa | ary-level | data from | the GWAS | S have | been publishe | d previo | usly. ¹⁹ C |)ata from |
|-----|-----------|-----------|------------|-------------|----------|------------------|----------|-----------------------|-----------|
| 386 | the | UK | Biobank | can | be | requested | via | their | website |
| 387 | (https:// | www.uk | biobank.ac | .uk/enable- | -your-re | esearch/apply-fe | or-acces | s). | |

388 Novelty and Relevance

389 What is New?

This Mendelian Randomisation study investigated the relation between
 genetically predicted hypertensive disorders of pregnancy and the risk of
 developing cardiovascular disease and several cardiovascular risk factors.

393 What is Relevant?

- The study found genetic liability to pre-eclampsia/eclampsia and gestational
 hypertension to be linked to a higher risk of cardiovascular disease events in
 both women and men.
- Earlier hypertension appears to be a main driver behind the relation of
 hypertensive disorders of pregnancy and increased cardiovascular risk.

399 Clinical/Pathophysiological implications?

Hypertensive disorders of pregnancy seem to be an indicator for individuals at
 higher cardiovascular disease risk later in life.

403 **References**

| 404 | 1. | Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, Ferre CD, |
|-----|----|---|
| 405 | | Kroelinger CD, Hayes DK, Barfield WD. Hypertensive Disorders in Pregnancy |
| 406 | | and Mortality at Delivery Hospitalization - United States, 2017-2019. MMWR |
| 407 | | Morb Mortal Wkly Rep. 2022;71:585–591. doi: 10.15585/mmwr.mm7117a1. |
| 408 | 2. | Global burden of 369 diseases and injuries in 204 countries and territories, |
| 409 | | 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. |
| 410 | | Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. |
| 411 | 3. | Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates |
| 412 | | of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol |
| 413 | | Reprod Biol. 2013;170:1–7. doi: 10.1016/j.ejogrb.2013.05.005. |
| 414 | 4. | Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. |
| 415 | | 2021;398:341–354. doi: 10.1016/S0140-6736(20)32335-7. |
| 416 | 5. | Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall |
| 417 | | DR, Warren CE, Adoyi G, Ishaku S. Hypertensive Disorders of Pregnancy: |
| 418 | | ISSHP Classification, Diagnosis, and Management Recommendations for |
| 419 | | International Practice. Hypertension. 2018;72:24–43. doi: |
| 420 | | 10.1161/HYPERTENSIONAHA.117.10803. |
| 421 | 6. | National High Blood Pressure Education Program Working Group on High Blood |
| 422 | | Pressure. Report of the National High Blood Pressure Education Program |
| 423 | | Working Group on High Blood Pressure in Pregnancy. American Journal of |
| 424 | | Obstetrics and Gynecology. 2000;183:s1-s22. doi: 10.1067/mob.2000.107928. |
| 425 | 7. | Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: |
| 426 | | prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40:213- |
| 427 | | 220. doi: 10.1038/hr.2016.126. |
| 428 | 8. | Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: |
| 429 | | systematic review of controlled studies. BMJ. 2005;330:565. doi: |
| 430 | | 10.1136/bmj.38380.674340.E0. |
| 431 | 9. | Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, |
| 432 | | Magee LA, Rana S, Vermunt JV, August P. Hypertension in Pregnancy: |
| 433 | | Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement |
| 434 | | From the American Heart Association. Hypertension. 2022;79:e21-e41. doi: |
| 435 | | 10.1161/HYP.0000000000000208. |
| | | |

436 10. Crump C, Sundquist J, McLaughlin MA, Dolan SM, Govindarajulu U, Sieh W,

- 437 Sundquist K. Adverse pregnancy outcomes and long term risk of ischemic heart
- 438 disease in mothers: national cohort and co-sibling study. *BMJ*.
- 439 2023;380:e072112. doi: 10.1136/bmj-2022-072112.
- 11. Rayes B, Ardissino M, Slob EAW, Patel KHK, Girling J, Ng FS. Association of
 Hypertensive Disorders of Pregnancy With Future Cardiovascular Disease.
- 442 *JAMA Netw Open.* 2023;6:e230034. doi: 10.1001/jamanetworkopen.2023.0034.
- 443 12. Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future
 444 Maternal Cardiovascular Risk. *J Am Heart Assoc.* 2018;7:e009382. doi:
- 445 10.1161/JAHA.118.009382.
- 446 13. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O,
- 447 Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, et al. Pregnancy
- 448 and Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res.*
- 449 2022;130:652–672. doi: 10.1161/CIRCRESAHA.121.319895.
- 450 14. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM,
- 451 Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, et al.
- 452 Strengthening the Reporting of Observational Studies in Epidemiology Using
- 453 Mendelian Randomization: The STROBE-MR Statement. *JAMA*.

454 2021;326:1614–1621. doi: 10.1001/jama.2021.18236.

- 455 15. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J,
 456 Green J, Matthews P, Pell J, et al. UK Biobank: Current status and what it
 457 means for epidemiology. *Health Policy and Technology*. 2012;1:123–126. doi:
- 458 10.1016/j.hlpt.2012.07.003.
- 459 16. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
- 460 P, Green J, Landray M, et al. UK biobank: an open access resource for
- 461 identifying the causes of a wide range of complex diseases of middle and old
- 462 age. *PLoS Med.* 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.
 463 17. Collins R. What makes UK Biobank special? *Lancet.* 2012;379:1173–1174. doi:
- 464 10.1016/S0140-6736(12)60404-8.
- 465 18. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
- 466 Vukcevic D, Delaneau O, O'Connell J, et al. Genome-wide genetic data on
- 467 ~500,000 UK Biobank participants. 2017. doi: 10.1101/166298.
- 468 19. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy TH, Guerrero RF,
 469 Schuermans A, Selvaraj MS, Patel AP, et al. Genome-wide meta-analysis

- 470 identifies novel maternal risk variants and enables polygenic prediction of
- 471 preeclampsia and gestational hypertension. 2022. doi:
- 472 10.1101/2022.11.30.22282929.
- 473 20. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J,
- 474 Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching
- 475 human genotype-phenotype associations. *Bioinformatics*. 2019;35:4851–4853.
- doi: 10.1093/bioinformatics/btz469.
- 477 21. Privé F, Luu K, Blum MGB, McGrath JJ, Vilhjálmsson BJ. Efficient toolkit
- 478 implementing best practices for principal component analysis of population
- 479 genetic data. *Bioinformatics*. 2020;36:4449–4457. doi:
- 480 10.1093/bioinformatics/btaa520.
- 481 22. Yavorska OO, Burgess S. MendelianRandomization: an R package for
 482 performing Mendelian randomization analyses using summarized data. *Int J*
- 483 *Epidemiol.* 2017;46:1734–1739. doi: 10.1093/ije/dyx034.
- Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
 pleiotropy in causal relationships inferred from Mendelian randomization
 between complex traits and diseases. *Nat Genet.* 2018;50:693–698. doi:
 10.1038/s41588-018-0099-7.
- 488 24. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN,
- 489 Gore GC, Ray JG, Nerenberg K, et al. Cardiovascular Disease-Related
- 490 Morbidity and Mortality in Women With a History of Pregnancy Complications.
- 491 *Circulation*. 2019;139:1069–1079. doi:
- 492 10.1161/CIRCULATIONAHA.118.036748.
- 493 25. Ardissino M, Slob EAW, Millar O, Reddy RK, Lazzari L, Patel KHK, Ryan D,
- 494 Johnson MR, Gill D, Ng FS. Maternal Hypertension Increases Risk of
- 495 Preeclampsia and Low Fetal Birthweight: Genetic Evidence From a Mendelian
- 496 Randomization Study. *Hypertension*. 2022;79:588–598. doi:
- 497 10.1161/HYPERTENSIONAHA.121.18617.
- 498 26. Malik R, Georgakis MK, Vujkovic M, Damrauer SM, Elliott P, Karhunen V,
- 499 Giontella A, Fava C, Hellwege JN, Shuey MM, et al. Relationship Between Blood
- 500 Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian
- 501 Randomization Analyses. *Hypertension*. 2021;77:2004–2013. doi:
- 502 10.1161/HYPERTENSIONAHA.120.16534.

503 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization

using the MR-Egger method. *Eur J Epidemiol*. 2017;32:377–389. doi:

505 10.1007/s10654-017-0255-x.

- 506 28. Bateman BT, Schumacher HC, Bushnell CD, Pile-Spellman J, Simpson LL,
- 507 Sacco RL, Berman MF. Intracerebral hemorrhage in pregnancy: frequency, risk
- factors, and outcome. *Neurology*. 2006;67:424–429. doi:
- 509 10.1212/01.wnl.0000228277.84760.a2.
- 510 29. Hung S-K, Lee M-S, Lin H-Y, Chen L-C, Chuang C-J, Chew C-H, Yu B-H, Yang
- 511 H-J, Hsu F-C, Chiou W-Y. Impact of Hypertensive Disorders of Pregnancy on
- 512 the Risk of Stroke Stratified by Subtypes and Follow-Up Time. *Stroke*.

513 2022;53:338–344. doi: 10.1161/STROKEAHA.121.034109.

- 514 30. Auger N, Fraser WD, Schnitzer M, Leduc L, Healy-Profitós J, Paradis G.
- 515 Recurrent pre-eclampsia and subsequent cardiovascular risk. *Heart*.
- 516 2017;103:235–243. doi: 10.1136/heartjnl-2016-309671.
- 31. Robillard P-Y, Dekker G, Scioscia M. The necessity to specify paternities in all
 obstetrical files in multigravidae. *J Reprod Immunol*. 2022;154:103747. doi:
 10.1016/j.jri.2022.103747.
- 520 32. Peters SAE, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total
- 521 cholesterol as a risk factor for coronary heart disease and stroke in women
- 522 compared with men: A systematic review and meta-analysis. *Atherosclerosis*.
- 523 2016;248:123–131. doi: 10.1016/j.atherosclerosis.2016.03.016.
- 524 33. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood
 525 AM, Lewington S, Sattar N, Packard CJ, et al. Major lipids, apolipoproteins, and
- 526 risk of vascular disease. *JAMA*. 2009;302:1993–2000. doi:

527 10.1001/jama.2009.1619.

529 Figure Legends

Figure 1. Sex-specific Mendelian Randomisation analysis of genetically proxied pre-eclampsia/eclampsia and risk of cardiovascular events. Results are from inverse variance weighted regression. Models were adjusted for age at baseline and the first 16 genetic principal components. Abbreviations: CI, confidence interval; CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial infarction; OR, odds ratio; SAH, subarachnoid haemorrhage.

Figure 2. Sex-specific Mendelian Randomisation analysis of genetically
proxied gestational hypertension and risk of cardiovascular events. Results are
from inverse variance weighted regression. Models were adjusted for age at baseline
and the first 16 genetic principal components. Abbreviations: CI, confidence interval;
CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial
infarction; OR, odds ratio; SAH, subarachnoid haemorrhage.

542 Figure 3. Sex-specific Mendelian Randomisation analysis of genetically 543 proxied pre-eclampsia/eclampsia and cardiovascular risk factors. Results are 544 from inverse variance weighted regression Results are from inverse variance 545 weighted regression. Models were adjusted for age at baseline and the first 16 546 genetic principal components. Abbreviations: ALAT, alanine aminotransferase; 547 aspartate aminotransferase; CI, confidence interval; GGT, gamma ASAT. 548 glutamyltransferase; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; 549 LDL, low-density lipoprotein.

Figure 4. Sex-specific Mendelian Randomisation analysis of genetically proxied gestational hypertension and cardiovascular risk factors. Results are from inverse variance weighted regression. Models were adjusted for age at baseline and the first 16 genetic principal components. Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; CI, confidence interval; GGT, gamma glutamyltransferase; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

557

558 Tables

559 **Table 1. Participant characteristics.**

| | Overall (n=487,203) | | Wome | en (n=264,160) | Men (n=223,043) | | |
|---|---------------------|--------------------------------------|---------|--------------------------------------|-----------------|--------------------------------------|--|
| Characteristic | N | Mean ± SD, median [IQR], N (%) | N | Mean ± SD, median [IQR], N (%) | N | Mean ± SD, median [IQR], N (%) | |
| Age, years | 487,203 | 56.5 ± 8.1 | 264,160 | 56.4 ± 8.0 | 223,043 | 56.7 ± 8.2 | |
| SBP, mmHg | 460,029 | 137.8 ± 18.7 | 249,189 | 135.2 ± 19.2 | 210,840 | 140.9 ± 17.5 | |
| DBP, mmHg | 460,034 | 82.2 ± 10.1 | 249,192 | 80.7 ± 10.0 | 210,842 | 84.1 ± 10.0 | |
| Hypertension | 474,896 | 224,331 (47.2%) | 264,054 | 117,037 (44.3%) | 210,842 | 107,294 (50.9%) | |
| Age at hypertension diagnosis, years | 117,548 | 50.6 ± 9.9 | 54,552 | 50.0 ± 10.8 | 62,996 | 51.2 ± 9.1 | |
| Body mass index, kg/m2 | 485,231 | 27.4 ± 4.8 | 263,213 | 27.1 ± 5.2 | 222,018 | 27.8 ± 4.2 | |
| Smoking status | 484,701 | | 262,851 | | 221,850 | | |
| Never | | 265,322 (54.7%) | | 156,643 (59.6%) | | 108,679 (49.0%) | |
| Ex | | 168,194 (34.7%) | | 82,760 (31.5%) | | 85,434 (38.5%) | |
| Current | | 51,185 (10.6%) | | 23,448 (8.9%) | | 27,737 (12.5%) | |
| Total cholesterol, mmol/L | 464,313 | 5.7 ± 1.1 | 251,599 | 5.9 ± 1.1 | 212,714 | 5.5 ± 1.1 | |
| HDL cholesterol, mmol/L | 424,993 | 1.4 ± 0.4 | 228,604 | 1.6 ± 0.4 | 196,389 | 1.3 ± 0.3 | |
| Triglycerides, mmol/L | 463,945 | 1.5 [1.0, 2.1] | 251,460 | 1.3 [1.0, 1.9] | 212,485 | 1.7 [1.2, 2.4] | |
| LDL cholesterol, mmol/L | 463,446 | 3.6 ± 0.9 | 251,188 | 3.6 ± 0.9 | 212,258 | 3.5 ± 0.9 | |
| Lipoprotein(a), nmol/L | 371,400 | 21.1 [9.6, 61.9] | 201,844 | 22.2 [9.9, 62.0] | 169,556 | 19.8 [9.2, 61.8] | |
| Apolipoprotein A1, g/L | 422,655 | 1.5 ± 0.3 | 226,557 | 1.6 ± 0.3 | 196,098 | 1.4 ± 0.2 | |
| Apolipoprotein B, g/L | 461,972 | 1.0 ± 0.2 | 250,732 | 1.0 ± 0.2 | 211,240 | 1.0 ± 0.2 | |
| HbA1c, mmol/mol | 462,868 | 36.1 ± 6.8 | 250,932 | 35.8 ± 6.0 | 211,936 | 36.5 ± 7.6 | |
| Creatinine, µmol/L | 464,085 | 70.4 [61.4, 80.9] | 251,489 | 63.1 [57.0, 70.0] | 212,596 | 80.0 [72.5, 88.4] | |
| Albumin, g/L | 425,194 | 45.2 ± 2.6 | 228,687 | 44.9 ± 2.6 | 196,507 | 45.5 ± 2.6 | |
| ALAT, U/L | 464,133 | 20.1 [15.4, 27.4] | 251,592 | 17.5 [13.9, 22.9] | 212,541 | 23.9 [18.4, 32.0] | |
| ASAT, U/L | 462,594 | 24.4 [21.0, 28.8] | 250,727 | 23.0 [20.0, 26.8] | 211,867 | 26.2 [22.6, 31.0] | |
| Gamma-GT, U/L | 464,074 | 26.3 [18.5, 41.0] | 251,496 | 21.4 [16.1, 31.9] | 212,578 | 33.1 [23.7, 50.3] | |
| C-reactive protein, mg/L | 463,305 | 1.3 [0.7, 2.8] | 251,162 | 1.4 [0.6, 3.0] | 212,143 | 1.3 [0.7, 2.5] | |

Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; DBP, diastolic blood pressure; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase;; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.

| (which was not certified by p | rg/10.1101/2023.03.14.2328/281; this version poste eer review) is the author/funder, who has granted m It is made available under a CC-BY 4.0 Intern | ed March 15, 2023. The copyright holder for this p nedRxiv a license to display the preprint in perpet pational license. | oreprint tuity. | Women-to-men | |
|-------------------------------|--|--|--------------------|-------------------|---------|
| Outcome | , in the made available and i a co br 4.6 mem | OR (95% CI) | P-value | ratio of ORs | P-value |
| CVD | | 1.20 (1.01, 1.43) | 0.040 | 0.93 (0.73, 1.19) | 0.583 |
| | | 1.29 (1.08, 1.53) | 0.004 | | |
| MI | | 1.22 (0.95, 1.57) | 0.115 | 0.92 (0.68, 1.24) | 0.592 |
| | | 1.33 (1.12, 1.57) | 0.001 | | |
| Stroke | | 1.17 (1.00, 1.37) | 0.051 | 0.94 (0.75, 1.16) | 0.553 |
| | | 1.25 (1.07, 1.45) | 0.004 | | |
| Ischaemic stroke | | 1.29 (1.07, 1.56) | 0.008 | 0.97 (0.73, 1.28) | 0.834 |
| | | 1.33 (1.09, 1.63) | 0.006 | | |
| Haemorrhagic stroke | | 1.05 (0.82, 1.34) | 0.704 | 1.16 (0.82, 1.66) | 0.403 |
| | | 0.90 (0.70, 1.16) | 0.427 | | |
| ICH | | 0.99 (0.71, 1.39) | 0.969 | 1.09 (0.69, 1.74) | 0.702 |
| | | 0.91 (0.66, 1.25) | 0.547 | | |
| SAH | _ | 1.02 (0.75, 1.38) | 0.908 | 1.22 (0.75, 1.99) | 0.426 |
| | | 0.83 (0.57, 1.22) | 0.353 | | |
| Ischaemic CVD | | 1.24 (1.02, 1.52) | 0.033 | 0.94 (0.72, 1.23) | 0.649 |
| | | 1.32 (1.10, 1.59) | 0.003 | | |
| | | | | | |
| | 0.50 1.0 | 2.0 | | | |
| | ■ Women ■ Men | | | | |

| medRxiv preprint doi: https://doi.c (which was not certified by p | rg/10.1101/2023 eer review) is the It is made | 3.03.14.23287281; ne author/funder, w available under a | this version po- ho has granted | sted March 1 d medRxiv a l | 2023. The copyright holder for this license to display the preprint in perperation | preprint etuity. | Women_to_men | |
|--|---|---|------------------------------------|-------------------------------|--|---------------------|-------------------|---------|
| Outcome | it is made | avallable under a | 00-D1 4.0 mie | | OR (95% CI) | P-value | ratio of ORs | P-value |
| CVD | | - | | | 1.22 (1.10, 1.36) | <0.001 | 0.96 (0.82, 1.11) | 0.548 |
| | | | | | 1.28 (1.16, 1.42) | <0.001 | | |
| MI | | - | -• | | 1.24 (1.09, 1.42) | 0.001 | 0.94 (0.80, 1.12) | 0.504 |
| | | | | | 1.32 (1.19, 1.46) | <0.001 | | |
| Stroke | | _ | • | | 1.23 (1.01, 1.49) | 0.043 | 1.01 (0.81, 1.27) | 0.910 |
| | | - | | | 1.21 (1.08, 1.36) | 0.001 | | |
| Ischaemic stroke | | - | • | | 1.24 (0.94, 1.63) | 0.131 | 0.95 (0.69, 1.31) | 0.769 |
| | | | | | 1.30 (1.11, 1.52) | 0.001 | | |
| Haemorrhagic stroke | | - | • | _ | 1.37 (1.07, 1.77) | 0.013 | 1.22 (0.74, 2.03) | 0.439 |
| | | | • | - | 1.12 (0.72, 1.75) | 0.603 | | |
| ICH | | - | • | | 1.33 (0.94, 1.89) | 0.111 | 1.34 (0.71, 2.53) | 0.360 |
| | | | | | 0.99 (0.59, 1.67) | 0.970 | | |
| SAH | | _ | • | | 1.39 (1.00, 1.93) | 0.051 | 1.09 (0.57, 2.09) | 0.788 |
| | | | • | \rightarrow | 1.27 (0.73, 2.22) | 0.397 | | |
| Ischaemic CVD | | - | | | 1.22 (1.10, 1.37) | <0.001 | 0.93 (0.79, 1.08) | 0.323 |
| | | | | | 1.32 (1.19, 1.47) | <0.001 | | |
| | [| | | | | | | |
| | 0.50 | 1.0 | | 2.0 | | | | |
| | | • Women • | Men | | | | | |

| Risk factor | | Beta (95% CI) | P-value | Women-to-men difference | P-value |
|--|---|--|---------------------------------|----------------------------|---------|
| Systolic blood pressure medRxiv preprint doi: https://doi.org/* | 10.1101/2023.03.14.23287281; this version pos | 0.16 (0.06, 0.26) ted March 15, 2023. 9h1 4 copying Replacer 2021 his prepl | 0.003 _{rint} <0.001 | 0.02 (-0.11, 0.15) | 0.764 |
| (which was not certified by peer Diastolic blood pressure | It is made available under a CC-BY 4.0 Inter | medRxiv a license to display the preprint in perpetuity. national license . 0.16 (0.04, 0.27) 0.16 (0.06, 0.26) | 0.006 0.002 | -0.00 (-0.15, 0.15) | 0.961 |
| Age at hypertension diagnosis | - - | -0.22 (-0.31, -0.12) -0.13 (-0.20, -0.06) | <0.001 <0.001 | -0.09 (-0.20, 0.03) | 0.154 |
| Body mass index | | 0.06 (-0.11, 0.23) 0.07 (-0.08, 0.23) | 0.460 0.357 | -0.01 (-0.24, 0.22) | 0.923 |
| Total cholesterol | | -0.06 (-0.12, -0.01) -0.11 (-0.18, -0.04) | 0.031 0.002 | 0.05 (-0.04, 0.14) | 0.295 |
| HDL cholesterol | | -0.04 (-0.10, 0.01) -0.07 (-0.13, -0.02) | 0.085 0.008 | 0.03 (-0.05, 0.10) | 0.453 |
| Triglycerides | | -0.02 (-0.06, 0.02) -0.02 (-0.07, 0.02) | 0.308 0.327 | 0.01 (-0.06, 0.07) | 0.848 |
| LDL cholesterol | | -0.05 (-0.10, 0.00) -0.09 (-0.16, -0.02) | 0.057 0.009 | 0.04 (-0.04, 0.13) | 0.347 |
| Lipoprotein(a) | † | 0.01 (-0.02, 0.03) 0.01 (-0.01, 0.04) | 0.638 0.346 | -0.01 (-0.04, 0.03) | 0.698 |
| Apolipoprotein A1 | | -0.03 (-0.07, 0.02) -0.06 (-0.09, -0.02) | 0.225 0.004 | 0.03 (-0.03, 0.09) | 0.286 |
| Apolipoprotein B | | -0.04 (-0.08, 0.01) -0.08 (-0.14, -0.02) | 0.088 0.009 | 0.04 (-0.03, 0.11) | 0.254 |
| HbA1c | - - | 0.01 (-0.05, 0.07) 0.03 (-0.06, 0.11) | 0.703 0.570 | -0.01 (-0.12, 0.09) | 0.801 |
| Creatinine | | -0.03 (-0.08, 0.02) -0.01 (-0.05, 0.03) | 0.235 0.691 | -0.02 (-0.09, 0.04) | 0.533 |
| Albumin | | -0.03 (-0.09, 0.03) -0.02 (-0.08, 0.04) | 0.345 0.436 | -0.00 (-0.09, 0.08) | 0.924 |
| ALAT | | 0.05 (-0.01, 0.11) 0.06 (-0.00, 0.13) | 0.078 0.068 | -0.01 (-0.10, 0.08) | 0.803 |
| ASAT | - - | 0.02 (-0.04, 0.07) 0.02 (-0.03, 0.08) | 0.549 0.436 | -0.01 (-0.08, 0.07) | 0.877 |
| GGT | + | -0.00 (-0.04, 0.03) -0.02 (-0.05, 0.02) | 0.866 0.322 | 0.01 (-0.03, 0.06) | 0.584 |
| C-reactive protein | - - | 0.03 (-0.03, 0.08) 0.02 (-0.04, 0.08) | 0.302 0.537 | 0.01 (-0.07, 0.09) | 0.811 |
| -C |).4 -0.2 0 0.2 (| ר).4 | | | |

Women Men

| Risk factor | | Beta (95% CI) | P-value | Women-to-men difference | P-value |
|--|--|---|----------------------------------|----------------------------|---------|
| Systolic blood pressure medRxiv preprint doi: https://doi.org/1 | 0.1101/2023.03.14.23287281; this version po | 0.22 (0.12, 0.32) sted March 15, 2023.9he copyright Polder 26this prep | <0.001 _{rint} <0.001 | 0.05 (-0.09, 0.18) | 0.498 |
| (which was not certified by peer Diastolic blood pressure | review) is the author/funder, who has granted It is made available under a CC-BY 4.0 Inte | medRxiv a license to display the preprint in perpetuity. rnational license . 0.19 (0.10, 0.29) 0.18 (0.09, 0.28) | <0.001 <0.001 | 0.01 (-0.12, 0.14) | 0.890 |
| Age at hypertension diagnosis | | -0.21 (-0.33, -0.09) -0.15 (-0.22, -0.09) | <0.001 <0.001 | -0.06 (-0.19, 0.08) | 0.420 |
| Body mass index | • | 0.00 (-0.02, 0.03) 0.01 (-0.02, 0.04) | 0.748 0.378 | -0.01 (-0.05, 0.03) | 0.661 |
| Total cholesterol | | -0.02 (-0.06, 0.02) -0.07 (-0.12, -0.01) | 0.389 0.021 | 0.05 (-0.02, 0.12) | 0.194 |
| HDL cholesterol | | -0.02 (-0.06, 0.01) -0.01 (-0.04, 0.02) | 0.234 0.468 | -0.01 (-0.06, 0.03) | 0.599 |
| Triglycerides | | -0.01 (-0.04, 0.03) -0.02 (-0.07, 0.02) | 0.692 0.224 | 0.02 (-0.03, 0.07) | 0.502 |
| LDL cholesterol | | -0.01 (-0.06, 0.04) -0.07 (-0.12, -0.01) | 0.643 0.018 | 0.06 (-0.02, 0.13) | 0.138 |
| Lipoprotein(a) | • | 0.01 (-0.02, 0.03) 0.00 (-0.03, 0.04) | 0.600 0.821 | 0.00 (-0.04, 0.05) | 0.928 |
| Apolipoprotein A1 | - | -0.01 (-0.06, 0.03) 0.00 (-0.02, 0.03) | 0.549 0.719 | -0.02 (-0.07, 0.03) | 0.484 |
| Apolipoprotein B | | -0.00 (-0.04, 0.04) -0.06 (-0.11, -0.01) | 0.922 0.023 | 0.06 (-0.01, 0.13) | 0.081 |
| HbA1c | + | 0.00 (-0.02, 0.02) 0.01 (-0.02, 0.03) | 0.975 0.665 | -0.01 (-0.04, 0.03) | 0.752 |
| Creatinine | - • - | -0.05 (-0.11, 0.01) -0.03 (-0.08, 0.01) | 0.111 0.173 | -0.02 (-0.09, 0.06) | 0.652 |
| Albumin | | 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) | 0.589 0.473 | -0.00 (-0.06, 0.05) | 0.864 |
| ALAT | • | 0.01 (-0.04, 0.05) 0.01 (-0.01, 0.03) | 0.784 0.438 | -0.00 (-0.05, 0.05) | 0.910 |
| ASAT | - | 0.00 (-0.04, 0.04) 0.01 (-0.01, 0.03) | 0.930 0.378 | -0.01 (-0.06, 0.04) | 0.699 |
| GGT | | 0.02 (-0.03, 0.06) 0.02 (-0.01, 0.06) | 0.492 0.231 | -0.01 (-0.06, 0.05) | 0.820 |
| C-reactive protein | • | 0.01 (-0.01, 0.03) 0.01 (-0.03, 0.05) | 0.375 0.648 | 0.00 (-0.05, 0.05) | 0.976 |
| -0 | 0.4 -0.2 0 0.2 | つ).4 | | | |

• Women • Men